Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.14213 http://scihub22266oqcxt.onion/10.1111/bjh.14213 C5096152!5096152 !27411022     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27411022 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Haematol 2016 ; 175 (2 ): 252-264 Nephropedia Template TP {{tp|p=27411022 |t=2016. Multiple myeloma: patient outcomes in real-world practice |pdf=|usr=}}{{27411022 }} gab.com Text Multiple myeloma: patient outcomes in real-world practice JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=27411022 #FOAvip With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first-line therapy was 6 months, followed by a median treatment-free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician-judged. Toxicities and co-morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice. Twit Text FOAVip Multiple myeloma: patient outcomes in real-world practice ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=27411022 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27411022 #FOAvip English Wikipedia <ref>{{Cite pmid|27411022 }}</ref> Multiple myeloma: patient outcomes in real-world practice #MMPMID27411022 Yong K ; Delforge M ; Driessen C ; Fink L ; Flinois A ; Gonzalez-McQuire S ; Safaei R ; Karlin L ; Mateos MV ; Raab MS ; Schoen P ; Cavo M Br J Haematol 2016[Oct]; 175 (2 ): 252-264 PMID27411022 show ga With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first-line therapy was 6 months, followed by a median treatment-free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician-judged. Toxicities and co-morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice. |Aged [MESH] |Aged, 80 and over [MESH] |Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use [MESH] |Comorbidity [MESH] |Cross-Sectional Studies [MESH] |Disease Management [MESH] |Disease Progression [MESH] |Europe/epidemiology [MESH] |Female [MESH] |Health Care Surveys [MESH] |Humans [MESH] |Male [MESH] |Middle Aged [MESH] |Multiple Myeloma/diagnosis/*epidemiology/therapy [MESH] |Outcome Assessment, Health Care [MESH] |Phenotype [MESH] |Physicians [MESH] |Retrospective Studies [MESH]Multiple myeloma: patient outcomes in real-world practice (epmc).pdf DeepDyve Pubget Overpricing